Vera Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $2.08B
- P/E (TTM)
- –
- Dividend yield
- –
About Vera Therapeutics
Pharmaceutical Preparations, SIC 2834
Vera Therapeutics, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing and commercializing therapies for individuals with severe immunological conditions. The company's primary product candidate is atacicept, a fusion protein designed for at-home self-administration via subcutaneous injection to treat autoimmune kidney conditions, most notably immunoglobulin A nephropathy. In addition to atacicept, its development programs involve investigational candidates such as MAU868 and VT-109 under licensing agreements. The company operates in the biotechnology sector and aims its investigational therapies at patients suffering from serious autoimmune and kidney disorders.
The company maintains its principal executive offices in Brisbane, California. Its operations and clinical research activities are conducted within the United States, supported by external partners for clinical trials and contract manufacturing. The provided text mentions no retail locations, operational facilities outside the United States, or additional branch offices.
Summary of the business section of Vera Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Vera Therapeutics, Inc.
- Headquarters
- Brisbane, CA
- Address
- 2000 Sierra Point Parkway, Suite 1200 94005
- Phone
- (650) 770-0077
- Website
- veratx.com
- Employees
- 249, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Francisco, California
Stock & identifiers
- Ticker
- VERA
- Exchange
- Nasdaq
- IPO date
- May 17, 2021
- Shares outstanding
- 72M, Jul 29, 2026
- Public float
- $1.30B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 23-for-2, May 7, 2021
- SEC CIK
- 1831828
- CUSIP
- 92337R101
- ISIN
- US92337R1014
- EIN
- 81-2744449
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Marshall Fordyce | PRESIDENT AND CEO, Director | 475,774 |
| Joseph R. Young | SVP, FINANCE, CHIEF ACCT OFFCR | 80,754 |
| Nancy Lee Boman | Chief Regulatory Officer | 44,987 |
| Jane Wright-Mitchell | Chief Legal Officer | 42,403 |
| Laurence Matthew Skelton | Chief Commercial Officer | 64,218 |
| Sean Grant | CHIEF FINANCIAL OFFICER | 119,181 |
| David Lee Johnson | Chief Operating Officer | 45,727 |
| William D. Turner | Chief Regulatory Officer | 45,313 |
| Robert Brenner | Chief Medical Officer | 50,947 |
| Jason S. Carter | Chief Legal Officer | 49,136 |
| Scott W. Morrison | Director | – |
| Michael Morrissey | Director | 0 |
| Andrew Cheng | Director | 17,488 |
| James R. Meyers | Director | – |
| Kimball Hall | Director | 0 |
| Christy J. Oliger | Director | 2,987 |
| Beth C. Seidenberg | Director | 135,565 |
| Patrick G. Enright | Director | 3,602,475 |
| Christopher Hite | Director | – |
| Maha Katabi | Director | 5,975,429 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Marshall Fordyce, M.D. | $6.99M | $9.13M | $2.63M | $262 | $137 |
| FY2024 Marshall Fordyce, M.D. | $5.65M | $31.24M | $5.05M | $219 | $103 |
| FY2023 Marshall Fordyce, M.D. | $3.43M | $1.99M | $1.39M | $79 | $105 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 249 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 17, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| May 11, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |